论文部分内容阅读
目的探讨血脂康对不稳定型心绞痛(UAP)患者血浆肿瘤坏死因子α(TNF-α)及超敏C反应蛋白(hsCRP)水平的影响。方法采用酶联免疫吸附法(ELISA)和免疫浊度法检测60例UAP患者服用血脂康前后血浆TNF-α及hsCRP水平。结果 UAP组血浆TNF-α、hsCRP水平为(23.34±6.32)ng/L、(2.27±0.44)μg/L,显著高于对照组的(19.85±5.17)ng/L和(1.98±0.41)μg/L(P<0.01),服用血脂康4周后UAP组血浆TNF-α及hsCRP水平明显下降(P<0.01)。结论血脂康可显著降低UAP患者血浆TNF-α及hsCRP水平,对改善UAP患者的预后有一定作用。
Objective To investigate the effects of Xuezhikang on plasma tumor necrosis factor α (TNF-α) and hsCRP in patients with unstable angina pectoris (UAP). Methods The levels of plasma TNF-α and hsCRP in 60 UAP patients before and after administration of Xuezhikang were measured by enzyme-linked immunosorbent assay (ELISA) and immunoturbidimetry. Results The plasma levels of TNF-α and hsCRP in UAP group were (23.34 ± 6.32) ng / L and (2.27 ± 0.44) μg / L, respectively, which were significantly higher than those in the control group (19.85 ± 5.17 ng / L and 1.98 ± 0.41 μg / L (P <0.01). After taking Xuezhikang for 4 weeks, the levels of plasma TNF-α and hsCRP in UAP group decreased significantly (P <0.01). Conclusion Xuezhikang can significantly reduce the levels of plasma TNF-α and hsCRP in patients with UAP and play a role in improving the prognosis of patients with UAP.